Page 22 - Haematologica May 2020

Editorials
References
1. Baliakas P, Jeromin S, Iskas M, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133(11):1205-1216.
2. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lympho- cytic leukemia. Trends Immunol. 2013;34(12):592-601.
3. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525-530.
region of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia. Haematologica. 2017;102(8):e305- e309.
24. Wu B, Słabicki M, Sellner L, et al. MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia. Br J Haematol. 2017;179(3):421-429.
25. Close V, Close W, Kugler SJ, et al. FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. Blood. 2019;133(8):830-839.
26. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an inde- pendent predictor of survival in chronic lymphocytic leukemia. Blood. 2012;119(2):521-529.
27. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247-3254.
28. Villamor N, Conde L, Martínez-Trillos A, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013;27(5):1100-1106.
29. Larrayoz M, Rose-Zerilli MJJ, Kadalayil L, et al. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial. Leukemia. 2017;31(2):510-514.
30. LópezC,DelgadoJ,CostaD,etal.Clonalevolutioninchroniclym- phocytic leukemia: Analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance. Genes Chromosom Cancer. 2013;52(10):920-927.
31. Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012;119(2):329-331.
32. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
33. Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4(9):1088-1101.
4. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473-4479.
5. Zenz T, Kröber A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term fol-
low-up. Blood. 2008;112(8):3322-3329.
6. DietrichS,OleśM,LuJ,etal.Drug-perturbation-basedstratification
of blood cancer. J Clin Invest. 2018;128(1):427-445.
7. Argelaguet R, Velten B, Arnol D, et al. Multi‐omics factor analysis— a framework for unsupervised integration of multi‐omics data sets.
Mol Syst Biol. 2018;14(6):e8124.
8. EdelmannJ,HolzmannK,TauschE,etal.Genomicalterationsinhigh-
risk chronic lymphocytic leukemia frequently affect cell cycle key reg- ulators and NOTCH1-regulated transcription. Haematologica. 2020;Volume 105(5):1379-1390.
9. Hong M, He J, Li S. SNW1 regulates Notch signaling in neuroblas- toma through interacting with RBPJ. Biochem Biophys Res Commun. 2019;509(4):869-876.
10. Fortini ME. Notch sgnaling: the core pathway and its posttransla- tional regulation. Dev Cell. 2009;16(5):633-647.
11. Pajcini KV, Speck NA, Pear WS. Notch signaling in mammalian hematopoietic stem cells. Leukemia. 2011;25(10):1525-1532.
12. Kojika S, Griffin JD. Notch receptors and hematopoiesis. Exp Hematol. 2001;29(9):1041-1052.
13. KridelR,MeissnerB,RogicS,etal.Wholetranscriptomesequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119(9):1963-1971.
14. Lee SY, Kumano K, Nakazaki K, et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lym- phoma. Cancer Sci. 2009;100(5):920-926.
15. Karube K, Martínez D, Royo C, et al. Recurrent mutations of NOTCH genes in follicular lymphoma identify a distinctive subset of tumours. J Pathol. 2014;234(3):423-430.
16. RosatiE,BaldoniS,DeFalcoF,etal.NOTCH1aberrationsinchronic lymphocytic leukemia. Front Oncol. 2018;8:229.
17. Puente XS, Beà S, Valdés-Mas R, et al. Non-coding recurrent muta- tions in chronic lymphocytic leukaemia. Nature. 2015;526(7574): 519-524.
18. Fabbri G, Holmes AB, Viganotti M, et al. Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2017;114(14):E2011-E2919.
19. IanniMDi,BaldoniS,RosatiE,etal.AnewgeneticlesioninB-CLL: A NOTCH1 PEST domain mutation. Br J Haematol. 2009;146(6): 689-691.
20. Rosati E, Sabatini R, Rampino G, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B- CLL cells. Blood. 2009;113(4):856-865.
21. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-1401.
34. RizzoP,OsipoC,ForemanK,GoldeT,OsborneB,MieleL.Rational targeting of Notch signaling in cancer. Oncogene. 2008;27(38):5124- 5131.
22. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
37. WuY,Cain-HomC,ChoyL,etal.Therapeuticantibodytargetingof individual Notch receptors. Nature. 2010;464(7291):1052-1057.
38. BaldoniS,DelPapaB,DorilloE,etal.Bepridilexhibitsanti-leukemic
activity associated with NOTCH1 pathway inhibition in chronic
lymphocytic leukemia. Int J Cancer. 2018;143(4):958-970.
39. Nguyen L, Papenhausen P, Shao H. The role of c-MYC in B-cell lym- phomas: diagnostic and molecular aspects. Genes (Basel). 2017;8(4).
40. Huh YO, Lin KIC, Vega F, et al. MYC translocation in chronic lym- phocytic leukaemia is associated with increased prolymphocytes
and a poor prognosis. Br J Haematol. 2008;142(1):36-44.
41. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic
leukemia/lymphoma. Genes Dev. 2006;20(15):2096-2109.
42. Ruas M, Peters G. The p16(INK4a)/CDKN2A tumor suppressor and
its relatives. Biochim Biophys Acta. 1998;1378(2):F115-177.
43. Prives C, Hall PA. The P53 pathway. J Pathol. 1999;187(1):112-126.
44. FabbriG,KhiabanianH,HolmesAB,etal.Geneticlesionsassociated
with chronic lymphocytic leukemia transformation to Richter syn- drome. J Exp Med. 2013;210(11):2273-2288.
23. BittoloT,PozzoF,BombenR,etal.Mutationsinthe3′untranslated
35. Rosati E, Sabatini R, De Falco F, et al. γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhi- bition, endoplasmic reticulum stress increase and notch down-regu- lation. Int J Cancer. 2013;132(8):1940-1953.
36. López-Guerra M, Xargay-Torrent S, Rosich L, et al. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia. 2015;29(1):96-106.
1182
haematologica | 2020; 105(5)